These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
o
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
For the quarterly period ended June 30, 2013
|
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
For the transition period from to
|
|
REALSOURCE RESIDENTIAL, INC.
|
|
(Exact name of registrant as specified in its charter)
|
|
Nevada
|
98-0371433
|
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
2089 East Fort Union Blvd.,
Salt Lake City, Utah
|
84121
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
|
(801) 601-2700
|
|
(Registrant’s telephone number, including area code)
|
|
Upstream Biosciences Inc.
50 West Liberty St., Suite 880,
Reno, NV, 89501
Former Fiscal Year:
September 30, 2012
|
|
(Former name, former address and former fiscal year, if changed since last report)
|
| o |
Large accelerated filer
|
o |
Accelerated filer
|
| o |
Non-accelerated filer
|
o |
Smaller reporting company
|
|
Page
|
|||
| 2 | |||
|
PART 1-FINANCIAL INFORMATION
|
|||
|
Item 1.
|
Financial Statements (unaudited)
|
||
| F-2 | |||
| F-3 | |||
| F-4 | |||
| F-5 | |||
| F-6 | |||
| F-7 | |||
| 3 | |||
| 3 | |||
| 3 | |||
| 5 | |||
| 5 | |||
| 5 | |||
| 5 | |||
| 5 | |||
| 5 | |||
| 6 | |||
| 7 | |||
|
·
|
our ability to implement our current stated business plan of acquiring, managing and holding real estate assets as a real estate investment trust;
|
|
|
·
|
our ability to establish and maintain our brand;
|
|
|
·
|
our ability to attract and retain key members of our management team;
|
|
|
·
|
our future financing plans;
|
|
|
·
|
our anticipated needs for working capital;
|
|
|
·
|
the anticipated trends in our industry;
|
|
|
·
|
our ability to expand operational capabilities;
|
|
|
·
|
competition existing today or that will likely arise in the future; and
|
|
|
·
|
our ability to establish a market for our common stock and operate as a public company.
|
|
Contents
|
Page(s)
|
|
|
F-2
|
||
|
F-3
|
||
|
F-4
|
||
|
F-5
|
||
|
F-6
|
||
|
F-7
|
|
RealSource Residential, Inc.
|
|
(Formerly Upstream Biosciences, Inc.)
|
|
( A Development Stage Company)
|
|
June 30,
2013 |
September 30,
2012 |
|||||||
|
(Unaudited)
|
||||||||
|
ASSETS
|
||||||||
|
CURRENT ASSETS:
|
||||||||
|
Cash
|
$
|
—
|
$
|
4,312
|
||||
|
Due from related party
|
705
|
—
|
||||||
|
Accounts receivable
|
900
|
—
|
||||||
|
Prepaid expenses
|
—
|
3,500
|
||||||
|
Total Current Assets
|
1,605
|
7,812
|
||||||
|
Total Assets
|
$
|
1,605
|
$
|
7,812
|
||||
|
LIABILITIES AND STOCKHOLDERS' DEFICIT
|
||||||||
|
CURRENT LIABILITIES:
|
||||||||
|
Accounts payable and accrued liabilities
|
$
|
—
|
$
|
24,576
|
||||
|
Advances from related parties
|
—
|
10,000
|
||||||
|
Total Current Liabilities
|
—
|
34,576
|
||||||
|
STOCKHOLDERS' EQUITY (DEFICIT):
|
||||||||
|
Preferred stock: $0.001 par value; 100,000,000 shares authorized;
none issued or outstanding
|
—
|
—
|
||||||
|
Common stock: $0.001 par value; 100,000,000 shares authorized;
11,975,645 and 1,975,645 shares issued and outstanding, respectively
|
11,975
|
1,975
|
||||||
|
Additional paid-in capital
|
7,215,770
|
7,190,770
|
||||||
|
Deficit accumulated during the development stage
|
(7,214,302
|
) |
(7,207,671
|
) | ||||
|
Accumulated other comprehensive income (loss):
|
||||||||
|
Foreign currency translation gain (loss)
|
(11,838
|
) |
(11,838
|
) | ||||
|
Total Stockholders' Equity (Deficit)
|
1,605
|
(26,764
|
) | |||||
|
Total Liabilities and Stockholders' Equity (Deficit)
|
$
|
1,605
|
$
|
7,812
|
||||
|
RealSource Residential, Inc.
|
|
(Formerly Upstream Biosciences, Inc.)
|
|
( A Development Stage Company)
|
|
|
|
For the Period
|
|
|||||||||
|
|
|
For the Nine Months
|
For the Nine Months
|
from June 14, 2004
|
|
|||||||
|
|
|
Ended
|
Ended
|
(inception) through
|
|
|||||||
|
|
|
June 30, 2013
|
June 30, 2012
|
June 30, 2013
|
|
|||||||
|
|
|
(Unaudited)
|
(Unaudited)
|
(Unaudited)
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues earned during the development stage
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
67,600
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization
|
|
|
—
|
|
|
|
—
|
|
|
|
133,600
|
|
|
Consulting fees
|
|
|
—
|
|
|
|
—
|
|
|
|
12,598
|
|
|
Investor and corporate communications
|
|
|
—
|
|
|
|
—
|
|
|
|
258,349
|
|
|
License fees and royalties
|
|
|
—
|
|
|
|
—
|
|
|
|
114,384
|
|
|
Management compensation
|
|
|
—
|
|
|
|
—
|
|
|
|
1,526,086
|
|
|
Research and development
|
|
|
—
|
|
|
|
—
|
|
|
|
1,421,530
|
|
|
Stock-based compensation
|
|
|
—
|
|
|
|
—
|
|
|
|
2,090,632
|
|
|
Loss on foreign exchange translations
|
|
|
—
|
|
|
|
—
|
|
|
|
15,544
|
|
|
Professional fees
|
|
|
14,370
|
|
|
|
14,940
|
|
|
|
664,832
|
|
|
General and administrative expenses
|
|
|
24,340
|
|
|
|
5,880
|
|
|
|
519,904
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
38,710
|
|
|
|
20,820
|
|
|
|
6,757,459
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations
|
|
|
(38,710
|
)
|
|
|
(20,820
|
)
|
|
|
(6,689,859
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other (income) expense:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Asset impairment loss
|
|
|
—
|
|
|
|
—
|
|
|
|
59,010
|
|
|
Compensation shares
|
|
|
—
|
|
|
|
—
|
|
|
|
25,000
|
|
|
Interest and finance charges
|
|
|
—
|
|
|
|
—
|
|
|
|
598,965
|
|
|
Interest income
|
|
|
—
|
|
|
|
—
|
|
|
|
(84,671
|
)
|
|
Loss on sale of intellectual property
|
|
|
—
|
|
|
|
—
|
|
|
|
78,570
|
|
|
(Gain) loss on sale of subsidiary
|
|
|
—
|
|
|
|
—
|
|
|
|
(126,515
|
)
|
|
Forgiveness of debt
|
|
|
(32,079
|
)
|
|
|
—
|
|
|
|
(32,079
|
)
|
|
Other (income) expense
|
|
|
—
|
|
|
|
—
|
|
|
|
(34,122
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other (income) expense
|
|
|
(32,079
|
)
|
|
|
—
|
|
|
|
484,158
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss before income tax provision
|
|
|
(6,631
|
)
|
|
|
(20,820
|
)
|
|
|
(7,174,017
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax provision
|
|
|
—
|
|
|
|
—
|
|
|
|
57,415
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(6,631
|
)
|
|
$
|
(20,820
|
)
|
|
$
|
(7,116,602
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- Basic and diluted
|
|
$
|
(0.00
|
)
|
|
$
|
(0.02
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- Basic and diluted
|
|
|
2,084,630
|
|
|
|
974,630
|
|
|
|
|
|
|
RealSource Residential, Inc.
|
|
(Formerly Upstream Biosciences, Inc.)
|
|
( A Development Stage Company)
|
|
For the Three Months
|
For the Three Months
|
|||||||
|
Ended
|
Ended
|
|||||||
|
June 30, 2013
|
June 30, 2012
|
|||||||
|
(Unaudited)
|
(Unaudited)
|
|||||||
|
Revenues earned during the development stage
|
$
|
—
|
$
|
—
|
||||
|
Operating expenses:
|
||||||||
|
Professional fees
|
1,000
|
9,950
|
||||||
|
General and administrative expenses
|
3,745
|
1,114
|
||||||
|
Total operating expenses
|
4,745
|
11,064
|
||||||
|
Loss from operations
|
(4,745
|
) |
(11,064
|
) | ||||
|
Other (income) expense:
|
||||||||
|
Forgiveness of debt
|
(32,079
|
) |
—
|
|||||
|
Total other (income) expense
|
(32,079
|
) |
—
|
|||||
|
Loss before income tax provision
|
27,334
|
(11,064
|
) | |||||
|
Income tax provision
|
—
|
—
|
||||||
|
Net loss
|
$
|
27,334
|
$
|
(11,064
|
) | |||
|
Net loss per common share:
|
||||||||
|
- Basic and diluted
|
$
|
0.01
|
$
|
(0.01
|
) | |||
|
Weighted average common shares outstanding:
|
||||||||
|
- Basic and diluted
|
2,140,630
|
974,630
|
||||||
|
RealSource Residential, Inc.
|
|
(Formerly Upstream Biosciences, Inc.)
|
|
( A Development Stage Company)
|
|
For the Period from June 14, 2004 (Inception) through June 30, 2013
|
|
(Unaudited)
|
|
Accumulated Other
|
||||||||||||||||||||||||
|
|
Comprehensive
|
|||||||||||||||||||||||
|
Common Stock Par
|
|
Deficit
|
Income (Loss)
|
|
||||||||||||||||||||
|
Value $0.001
|
Accumulated | Foreign | Total | |||||||||||||||||||||
|
Number
|
Additional
|
during the
|
Currency
|
Stockholders'
|
||||||||||||||||||||
|
of
Shares
|
Amount
|
Paid-in
Capital
|
Development
Stage |
Translation
Gain (Loss) |
Equity
(Deficit)
|
|||||||||||||||||||
|
Balance, June 14, 2004 (Inception)
|
1,694,286 | $ | 1,694 | $ | 47,306 | $ | (77,105 | ) | $ | — | $ | (28,105 | ) | |||||||||||
|
Forward stock split
|
847,143 | 847 | (847 | ) | — | |||||||||||||||||||
|
Comprehensive income (loss)
|
||||||||||||||||||||||||
|
Foreign currency translation gain (loss)
|
(3,472 | ) | (3,472 | ) | ||||||||||||||||||||
|
Net loss
|
(50,205 | ) | (50,205 | ) | ||||||||||||||||||||
|
Balance, December 31, 2005
|
2,541,429 | 2,541 | 46,459 | (127,310 | ) | (3,472 | ) | (81,782 | ) | |||||||||||||||
|
Shares issued to former shareholders of Upstream Canada
|
685,714 | 686 | 23,314 | 24,000 | ||||||||||||||||||||
|
Shares cancelled on acquisition
|
(1,961,429 | ) | (1,961 | ) | (66,689 | ) | (68,650 | ) | ||||||||||||||||
|
Recapitalization adjustment
|
(4,005 | ) | (49,045 | ) | (53,050 | ) | ||||||||||||||||||
|
Issuance of common stock to consultant at $1.20 per share
|
14,286 | 14 | 599,986 | 600,000 | ||||||||||||||||||||
|
Amortization of fair value of stock options granted
|
100,150 | 100,150 | ||||||||||||||||||||||
|
Fair value of detachable warrants
|
360,964 | 360,964 | ||||||||||||||||||||||
|
Embedded beneficial conversion feature
|
268,108 | 268,108 | ||||||||||||||||||||||
|
Common stock issued for future services
|
500 | — | 17,768 | — | ||||||||||||||||||||
|
Less amount expensed
|
14,986 | |||||||||||||||||||||||
|
Issuance of stock for BCCA license fee
|
845 | 1 | 17,746 | 17,747 | ||||||||||||||||||||
|
Partial forfeiture of convertible debenture
|
141,844 | 141,844 | ||||||||||||||||||||||
|
Comprehensive income (loss)
|
||||||||||||||||||||||||
|
Foreign currency translation gain (loss)
|
(5,707 | ) | (5,707 | ) | ||||||||||||||||||||
|
Net loss
|
(1,843,529 | ) | (1,843,529 | ) | ||||||||||||||||||||
|
Balance, September 30, 2006
|
1,281,345 | 1,281 | 1,505,645 | (2,019,884 | ) | (9,179 | ) | (524,919 | ) | |||||||||||||||
|
Amortization of fair value of stock options granted
|
771,809 | 771,809 | ||||||||||||||||||||||
|
Amortization of stock issued for operating expenses
|
2,782 | |||||||||||||||||||||||
|
Common stock issued for future services
|
1,381 | 1 | 34,721 | — | ||||||||||||||||||||
|
Less amount expensed
|
31,600 | |||||||||||||||||||||||
|
Common stock issued for cash at $1.50 per share
|
38,095 | 38 | 1,999,962 | 2,000,000 | ||||||||||||||||||||
|
Cash payment for unsuccesful due diligence
|
(5,000 | ) | (5,000 | ) | ||||||||||||||||||||
|
Convertible debentures converted to common stock
|
22,857 | 23 | 799,977 | 800,000 | ||||||||||||||||||||
|
Interest on convertible debt converted to common stock
|
1,542 | 2 | 53,971 | 53,973 | ||||||||||||||||||||
|
Common stock issued for acquisition of PPT
|
14,857 | 15 | 244,385 | 244,400 | ||||||||||||||||||||
|
Common stock issued as performance based escrow shares
|
6,429 | 7 | 105,743 | — | ||||||||||||||||||||
|
Obligation to issue shares under contract
|
4,842 | |||||||||||||||||||||||
|
Comprehensive income (loss)
|
||||||||||||||||||||||||
|
Foreign currency translation gain (loss)
|
36,035 | 36,035 | ||||||||||||||||||||||
|
Net loss
|
(1,796,981 | ) | (1,796,981 | ) | ||||||||||||||||||||
|
Balance, September 30, 2007
|
1,366,506 | 1,367 | 5,511,213 | (3,816,865 | ) | 26,856 | 1,618,541 | |||||||||||||||||
|
Amortization of fair value of stock options granted
|
424,128 | 424,128 | ||||||||||||||||||||||
|
Amortization of stock issued for operating expenses
|
3,122 | |||||||||||||||||||||||
|
Common stock issued for future services ending
January 31, 2008 at $0.30 per share
|
2,377 | 2 | 24,953 | 20,113 | ||||||||||||||||||||
|
Common stock issued for amended and restated contract
at $0.25 per share
|
11,525 | 12 | 100,836 | 135,570 | ||||||||||||||||||||
|
Common stock issued for future services ending
January 31, 2008 at $0.30 per share
|
6,106 | 6 | 47,049 | 81,777 | ||||||||||||||||||||
|
Common stock issued for achieving Malaria milestone
at $0.3624 per share
|
26,429 | 26 | 335,194 | 335,220 | ||||||||||||||||||||
|
Release of 75,000 shares from escrow
|
27,180 | |||||||||||||||||||||||
|
Obligation to issue shares under contract
|
14,391 | |||||||||||||||||||||||
|
Comprehensive income (loss)
|
||||||||||||||||||||||||
|
Foreign currency translation gain (loss)
|
(7,657 | ) | (7,657 | ) | ||||||||||||||||||||
|
Net loss
|
(2,034,502 | ) | (2,034,502 | ) | ||||||||||||||||||||
|
Balance, September 30, 2008
|
1,412,943 | 1,413 | 6,443,373 | (5,851,367 | ) | 19,199 | 548,439 | |||||||||||||||||
|
Amortization of fair value of stock options granted
|
194,545 | 194,545 | ||||||||||||||||||||||
|
Forgiveness of related party debt
|
300,000 | 300,000 | ||||||||||||||||||||||
|
Obligation to issue shares under contract
|
85,346 | |||||||||||||||||||||||
|
Comprehensive income (loss)
|
||||||||||||||||||||||||
|
Foreign currency translation gain (loss)
|
(29,237 | ) | (29,237 | ) | ||||||||||||||||||||
|
Net loss
|
(1,099,854 | ) | (1,099,854 | ) | ||||||||||||||||||||
|
Balance, September 30, 2009
|
1,412,943 | 1,413 | 6,937,918 | (6,951,221 | ) | (10,038 | ) | (761 | ) | |||||||||||||||
|
Forgiveness of related party debt
|
271,984 | 271,984 | ||||||||||||||||||||||
|
Issuance of common stock per agreement
|
28,571 | 29 | 24,971 | 25,000 | ||||||||||||||||||||
|
Common stock returned to treasury
|
(466,884 | ) | (467 | ) | 467 | — | ||||||||||||||||||
|
Forgiveness of obligation to issue shares under contract
|
(99,737 | ) | ||||||||||||||||||||||
|
Forgiveness of deferred compensation due to
cancellation of escrow shares
|
(78,570 | ) | — | |||||||||||||||||||||
|
Comprehensive income (loss)
|
||||||||||||||||||||||||
|
Foreign currency translation gain (loss)
|
(16,015 | ) | (16,015 | ) | ||||||||||||||||||||
|
Net loss
|
(323,544 | ) | (323,544 | ) | ||||||||||||||||||||
|
Balance, September 30, 2010
|
974,630 | 975 | 7,156,770 | (7,274,765 | ) | (26,053 | ) | (143,073 | ) | |||||||||||||||
|
Comprehensive income (loss)
|
||||||||||||||||||||||||
|
Foreign exchange translation adjustment
|
15,701 | 15,701 | ||||||||||||||||||||||
|
Net income
|
68,857 | 68,857 | ||||||||||||||||||||||
|
Balance, September 30, 2011
|
974,630 | 975 | 7,156,770 | (7,205,908 | ) | (10,352 | ) | (58,515 | ) | |||||||||||||||
|
Share issued for cash
|
1,000,000 | 1,000 | 34,000 | 35,000 | ||||||||||||||||||||
|
Comprehensive income (loss)
|
||||||||||||||||||||||||
|
Foreign currency translation gain (loss)
|
(1,486 | ) | (1,486 | ) | ||||||||||||||||||||
|
Net loss
|
(1,763 | ) | (1,763 | ) | ||||||||||||||||||||
|
Balance, September 30, 2012
|
1,974,630 | 1,975 | 7,190,770 | (7,207,671 | ) | (11,838 | ) | (26,764 | ) | |||||||||||||||
|
Common stock issued for debt
|
10,000,000 | 10,000 | 25,000 | 35,000 | ||||||||||||||||||||
|
Net loss
|
(6,631 | ) | (6,631 | ) | ||||||||||||||||||||
|
Balance, June 30, 2013
|
11,974,630 | $ | 11,975 | $ | 7,215,770 | $ | (7,214,302 | ) | $ | (11,838 | ) | $ | 1,605 | |||||||||||
|
RealSource Residential, Inc.
|
|||||||||||||||||||||||||
|
(Formerly Upstream Biosciences, Inc.)
|
|||||||||||||||||||||||||
|
(A Development Stage Company)
|
|||||||||||||||||||||||||
|
For the Nine Months
|
For the Nine Months
|
For the Period from
June 14, 2004
(inception)
|
|
|||||||||
|
Ended
|
Ended
|
through
|
|
|||||||||
|
June 30, 2013
|
June 30, 2012
|
June 30, 2013
|
|
|||||||||
|
(Unaudited)
|
(Unaudited)
|
(Unaudited)
|
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(6,631)
|
|
|
$
|
(20,820)
|
|
|
$
|
(7,116,602)
|
|
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization
|
|
|
—
|
|
|
|
—
|
|
|
|
133,600
|
|
|
Accretion of convertible debenture
|
|
|
—
|
|
|
|
—
|
|
|
|
302,808
|
|
|
Shares issued or to be issued for services
|
|
|
—
|
|
|
|
—
|
|
|
|
1,487,236
|
|
|
Stock-based compensation
|
|
|
—
|
|
|
|
—
|
|
|
|
1,658,590
|
|
|
Compensation shares
|
|
|
—
|
|
|
|
—
|
|
|
|
25,000
|
|
|
Deferred income tax
|
|
|
—
|
|
|
|
—
|
|
|
|
(57,415)
|
|
|
Asset impairment
|
|
|
—
|
|
|
|
—
|
|
|
|
59,010
|
|
|
Gain on sale of subsidiary
|
|
|
—
|
|
|
|
—
|
|
|
|
(126,515)
|
|
|
Loss from sale of intellectual property
|
|
|
—
|
|
|
|
—
|
|
|
|
78,570
|
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Due from related party
|
|
|
(705)
|
|
|
|
—
|
|
|
|
(705)
|
|
|
Accounts receivable
|
|
|
(900)
|
|
|
|
—
|
|
|
|
(900)
|
|
|
Prepaid expenses
|
|
|
3,500
|
|
|
|
(854)
|
|
|
|
(2,781)
|
|
|
Other receivables
|
|
|
—
|
|
|
|
—
|
|
|
|
(10,259)
|
|
|
Accounts payable and accrued liabilities
|
|
|
(24,576)
|
|
|
|
11,022
|
|
|
|
231,407
|
|
|
Due to related parties
|
|
|
—
|
|
|
|
—
|
|
|
|
271,984
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in operating activities
|
|
|
(29,312)
|
|
|
|
(10,652)
|
|
|
|
(3,066,972)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash paid for acquisition of PPT shares
|
|
|
—
|
|
|
|
—
|
|
|
|
(51,507)
|
|
|
Proceeds from the sale of subsidiary
|
|
|
—
|
|
|
|
—
|
|
|
|
1
|
|
|
Purchase of equipment
|
|
|
—
|
|
|
|
—
|
|
|
|
(22,764)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in investing activities
|
|
|
—
|
|
|
|
—
|
|
|
|
(74,270)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of convertible debentures
|
|
|
—
|
|
|
|
—
|
|
|
|
1,000,000
|
|
|
Proceeds from issuance of common shares, net
|
|
|
35,000
|
|
|
|
—
|
|
|
|
2,065,345
|
|
|
Advances from (repayment made to) related party
|
|
|
(10,000)
|
|
|
|
10,000
|
|
|
|
78,487
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by financing activities
|
|
|
25,000
|
|
|
|
10,000
|
|
|
|
3,143,832
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash
|
|
|
—
|
|
|
|
56
|
|
|
|
(2,590)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net change in cash
|
|
|
(4,312)
|
|
|
|
(596)
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash at beginning of period
|
|
|
4,312
|
|
|
|
12,602
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash at end of period
|
|
$
|
—
|
|
|
$
|
12,006
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure of cash flows information:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest paid
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Income tax paid
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Level 1
|
Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
|
|
|
Level 2
|
Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
|
|
|
Level 3
|
Pricing inputs that are generally observable inputs and not corroborated by market data.
|
|
·
|
Expected term of share options and similar instruments: The expected life of options and similar instruments represents the period of time the option and/or warrant are expected to be outstanding. Pursuant to Paragraph 718-10-50-2(f)(2)(i) of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and employees’ expected exercise and post-vesting employment termination behavior into the fair value (or calculated value) of the instruments. Pursuant to paragraph 718-10-S99-1, it may be appropriate to use the
simplified method
,
i.e.,
expected term = ((vesting term + original contractual term) / 2)
, if (i) A company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded; (ii) A company significantly changes the terms of its share option grants or the types of employees that receive share option grants such that its historical exercise data may no longer provide a reasonable basis upon which to estimate expected term; or (iii) A company has or expects to have significant structural changes in its business such that its historical exercise data may no longer provide a reasonable basis upon which to estimate expected term. The Company uses the simplified method to calculate expected term of share options and similar instruments as the company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term.
|
|
·
|
Expected volatility of the entity’s shares and the method used to estimate it. Pursuant to ASC Paragraph 718-10-50-2(f)(2)(ii)
a thinly-traded or nonpublic entity that uses the calculated value method shall disclose the reasons why it is not practicable for the Company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index. The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility. If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market.
|
|
·
|
Expected annual rate of quarterly dividends. An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends. The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected contractual life of the option and similar instruments.
|
|
·
|
Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the contractual life of the option and similar instruments.
|
|
·
|
Expected term of share options and similar instruments: Pursuant to Paragraph 718-10-50-2 of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and holder’s expected exercise behavior into the fair value (or calculated value) of the instruments. The Company uses historical data to estimate holder’s expected exercise behavior. The contractual term of share options or similar instruments is used as expected term of share options or similar instruments for the Company if it is a newly formed corporation.
|
|
·
|
Expected volatility of the entity’s shares and the method used to estimate it. An entity that uses a method that employs different volatilities during the contractual term shall disclose the range of expected volatilities used and the weighted-average expected volatility. A thinly-traded or nonpublic entity that uses the calculated value method shall disclose the reasons why it is not practicable for the Company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index. The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility. If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market.
|
|
·
|
Expected annual rate of quarterly dividends. An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends. The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected contractual life of the option and similar instruments.
|
|
·
|
Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the contractual life of the option and similar instruments.
|
|
No.
|
Description of Exhibit
|
|
|
31.1
|
||
|
31.2
|
||
|
32.1
|
||
|
32.2
|
||
|
101.INS *
|
XBRL Instance Document
|
|
|
101.CAL *
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
|
101.SCH *
|
XBRL Taxonomy Extension Schema Document
|
|
|
101.DEF *
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
|
101.LAB *
|
XBRL Taxonomy Extension Labels Linkbase Document
|
|
|
101.PRE *
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
*
|
XBRL (eXtensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.
|
|
Date: August
14
, 2013
|
RealSource Residential, Inc. | |
| By: |
/s/
Nathan W. Hanks
|
|
| Name: |
Nathan W. Hanks
|
|
| Title: |
President and Chief Executive Officer
|
|
| By: |
/s/
V. Kelly Randall
|
|
| Name: |
V. Kelly Randall
|
|
| Title: |
Chief Operating Officer and Chief Financial Officer
|
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|